• Mashup Score: 31
    Germline Genetic Testing After Cancer Diagnosis - 2 year(s) ago

    This observational study describes the prevalence of germline genetic testing in California and Georgia between 2013 and 2019 among patients diagnosed with cancer.

    Source: jamanetwork.com
    Categories: Hem/Oncs, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of Aiims1742
      Aiims1742

      Among 1.3 million patients Dxed with cancer between 2013 & 2019, ~93,000 (6.8%) underwent germline testing through 2021. The rate of germline mutation testing in #PancreaticCancer - where universal testing is a @NCCN & @ASCO guideline - was a mere 5.6%! šŸ¤¦šŸ½ā€ā™‚ļø https://t.co/Dmk4lhqNvL https://t.co/62sjBXTSpK

    • Profile photo of EricTopol
      EricTopol

      For patients with cancer, assessment for the potential of familial (germline) pathogenic mutations (like #BRCA) is recommended, but infrequently performed. When done, it's very informative https://t.co/enx6QiJ97I @JAMA_current https://t.co/0Pv3UJNORC

  • Mashup Score: 0
    Applying genetic principles to treatment of BRCA-mutant cancers - The Institute of Cancer Research, London - 2 year(s) ago

    Photo: Luke Henry, the ICRWe demonstrated that drugs called PARP inhibitors could be particularly effective in BRCA-mutant cancers and, with The Royal Marsden NHS Foundation Trust, helped run clinical trials leading to the first PARP inhibitor being licensed in ovarian cancer. The PARP inhibitor story began back in the mid-1990s, when a team of researchers at The Institute of Cancer Research ā€“…

    Source: www.icr.ac.uk
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of ICR_London
      ICR_London

      These crucial trials led to major changes in the treatment of #OvarianCancer, by using, for the first time, new targeted drugs to treat patients with mutations in their #BRCA genes. https://t.co/8W5SOcdjIx https://t.co/2pXOZmEQ7u

  • Mashup Score: 2
    Jewish Women and BRCA Gene Mutations | Bring Your Brave | CDC - 2 year(s) ago

    Ashkenazi Jewish women are 10 times more likely to have a BRCA1 or BRCA2 gene mutation than women in the general United States population.

    Source: www.cdc.gov
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of theNCI
      theNCI

      šŸ§µ(2/3) Ashkenazi Jews are more likely than most other groups to carry inherited genetic changes in BRCA1 and BRCA2 that increase their risk of breast and several other cancers. https://t.co/5tYgkWVgHm. #BRCA #BCSM #JewishAmericanHeritageMonth #BringYourBrave https://t.co/iTu9V7aGvd

  • Mashup Score: 3
    Niraparib plus nivolumab or niraparib plus ipilimumab in patients with platinum-sensitive advanced pancreatic cancer: a randomised, phase 1b/2 trial - PubMed - 2 year(s) ago

    Bristol Myers Squibb, GlaxoSmithKline, the Basser Center Young Leadership Council, The Konner Foundation, The Pearl and Philip Basser Innovation Research Award, the Anonymous Foundation, and the US National Institutes of Health.

    Source: PubMed
    Categories: Hem/Oncs, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of pashtoonkasi
      pashtoonkasi

      @BrunoBockorny @TumorBoardTues @OncoAlert @OncBrothers @Aiims1742 @PancPathologist @PanCAN @PancreaticCanUK @drallysonocean @ShaalanBeg @VivekSubbiah @BenWestphalen @MPishvaian @marklewismd @UmutDisel @Dr_R_Kurzrock @PeterHoseinMD @JAMAOnc šŸ’”The #immunotherapy & #BRCA story appears to be more CTLA4ā›”ļø>>>PD1/PDL1ā›”ļø. BRCA1/2/PALB2: in the niraparib plus ipilimumab group, PFS 10Ā·4 months (1Ā·5ā€“19Ā·2) OS was 38Ā·0 months (not estimable). @KReissMDā€™s data @OncoAlert šŸ‘‡šŸ¾ A PARPāž•PD1 B PARPāž•CTLA4 https://t.co/DT38mRJgVt https://t.co/rKW03oaUVi

  • Mashup Score: 5
    ICR hails ā€˜momentousā€™ recommendation of olaparib for breast and prostate cancer - 2 year(s) ago

    The Institute of Cancer Research, London, has hailed the ā€˜life-changingā€™ decision by NICE to recommend that the targeted drug olaparib can be used for NHS patients with both early-stage breast cancer and prostate cancer.

    Source: www.icr.ac.uk
    Categories: Hem/Oncs, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of cdanicas
      cdanicas

      RT @ICR_London: Last week, the drug, olaparib was recommended for NHS patients with advanced #ProstateCancer: https://t.co/PkrtplEZP6 Theā€¦

    • Profile photo of ICR_London
      ICR_London

      Last week, the drug, olaparib was recommended for NHS patients with advanced #ProstateCancer: https://t.co/PkrtplEZP6 The ICR and @royalmarsdenNHS led clinical trials that showed that olaparib was effective for patients with a range of cancers with #BRCA 1/2 mutations ā¬‡ļø https://t.co/Ux2WUs6HCL

  • Mashup Score: 1
    Nationwide Trends and Determinants of Germline BRCA1/2 Testing in Patients With Breast and Ovarian Cancer - 2 year(s) ago

    Background: Germline genetic testing (GT) for BRCA1/2 is instrumental in identifying patients with breast and ovarian cancers who are eligible for PARP inhibitors (PARPi). Little is known about recent trends and determinants of GT since PARPi were approved for these patients. Patients and Methods: We performed a retrospective cohort study of patients in a nationwide electronic health record…

    Source: JNCCN
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of JNCCN
      JNCCN

      Nationwide Trends and Determinants of Germline #BRCA 1/2 Testing in Patients With #BreastCancer and #OvarianCancer: https://t.co/ua8HcHNC3o #GynCSM #BCSM #genetictesting #hsronc by @KelseyLauMin @annemckn1 @klnathanson & Susan Domchek, MD @BasserBRCA https://t.co/T4GHZw4Btm

Load More